http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
황일용 대한신장학회 1994 Kidney Research and Clinical Practice Vol.13 No.1
Glomerulonephritis can develop when antibody reacts either with insoluble tissue-fixed glomerular antigens (structural or planted) or when soluble antigens (exogenous or endogenous) and antibodies in the circulation form immune complexes that subsequently accumulate in glomeruli. Membranous glomerulonephritis is known as the typical autoimmune disease in kidney diseases. This experiment reports the result of isolation of an autoantigen in the idiopathic membranous glomerulonephritis. The serum from 10 patients of idiopathic membranous glomerulonephritis confirmed by renal biopsy was used as the circulating primary antibody. After electrophoresis and Western blot with crude extraction of nephrectomized normal human kidney due to traffic accident, the primary antibody (patient's and normal control serum) was added to the tranblotted nitrocellulose membrane which contained the normal human kidney tissue. And then secondary antibody of phosphate labelled affinity purified antobody to human IgG (y) was tagged to the primary antobody on the transblotted membrane and stained by BCIP (5-bromo-4-chloro-3-indolyl-phosphate)/NBT (nitroblue tetrazolium). The 43 kD band was identified on the immunoblotting of the serum from 7 of 10 idiopathic membranous glomeluronephritis patients, not from normal control serum.
황일용(Il Yong Hwang),김건호(Gun Ho Kim) 대한내과학회 1994 대한내과학회지 Vol.47 No.6
Objectives: This study deals with the therapeutic effects of continuous intestinal dialysis (CID) by oral non-absorbable mannitol solutions (NAMS) on chronic uremic patients. Methods: CID was carried out in 28 chronic uremic patients who had creatinine clearance of 7.6±4.3 ml/ min and drank 200~250 ml NAMS every sixth hour for 2 to 6 months. Results: Before CID, blood urea nitrogen (BUN), serum creatinine (SCr), serum phosphorus (SP), serum uric acid (SUa), and serum potassium (SK) were 90.1±32.2, 10.6±3.2, 6.3±1.6, 9.5±2.9mg/dl, and 4.8±0.3 mmol/1, respectively. During the 2 months of CID, BUN, SCr, SP, SUa, and SK were significantly lowered to 66.4±24.1, 9.0±3.1, 5.2±1.5, 8.3±2.4 mg/dl, and 4.5±0.8 mmol/dl from those before CID (p<0.05). In 9 chronic uremic patients who stopped the CID by themselves for 2 weeks after 2 months of CID, BUN, SCr, SP, and SUa increased to the levels of 104.2±32.8, 11.7±3.2, 7.6±2.2, and 10.9±3.2 mg/dl as compared to 63.6±25.7, 8.2±2.6, 4.9±1.5, and 7.7±2.4 mg/dl during CID of the same 9 patients (p<0.05). There were no significant changes in body weight, serum calcium, serum sodium, serum chloride, hemoglobin, hematocrit, and RBC counts (p>0.05). The high performance gel chromatography has been applied to sera from the chronic uremic patients before and during CID. Integrated absorbance of 3 peaks which corresponded low to middle molecule weight range (less than 1,500 daltons) significantly decreased during CID when compared with those before CID (p<0.05). Conclusion: From these clinical results, the CID by oral NAMS can be well tolerated, remove the uremic toxins, improve uremic symptoms and be a new approach to the replacement therapy of chronic uremic patients.